Amgen (AMGN) SVP & CCO Nancy Grygiel receives 2,010-share equity grant

Rhea-AI Filing Summary

Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel received an equity award of 2,010 shares of Amgen common stock on March 3, 2026. The award is recorded at a price of $0.00 per share, reflecting a grant rather than an open-market purchase.

After this grant, she directly holds 9,249 Amgen shares. A footnote states this total includes 110 dividend equivalents credited under Amgen’s equity incentive plan, which convert to common shares as related restricted stock units vest. She also indirectly holds 105.465 Amgen shares through the company’s 401(k) plan stock fund.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Grygiel Nancy A.

Role SVP & CCO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,010	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 9,249 shares (Direct); Common Stock — 105.465 shares (Indirect, 401(k) Plan)

Footnotes (1)

1. These shares include 110 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grygiel Nancy A.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CCO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		2,010	A	$0	9,249(1)	D
Common Stock								105.465(2)	I	401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 110 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

2. These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

	/s/ Nancy A. Grygiel	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Amgen (AMGN) executive Nancy Grygiel report in this Form 4 filing?

Nancy A. Grygiel reported receiving a grant of 2,010 shares of Amgen common stock on March 3, 2026. The filing shows this as an equity award at $0.00 per share, increasing her directly held stake and detailing related dividend equivalents and 401(k) holdings.

How many Amgen (AMGN) shares does Nancy Grygiel hold after this reported grant?

After the reported equity grant, Nancy A. Grygiel directly holds 9,249 shares of Amgen common stock. The filing also shows an additional 105.465 shares held indirectly through Amgen’s 401(k) plan stock fund, providing a fuller picture of her total reported ownership.

What is the nature of the 2,010 Amgen (AMGN) shares granted to Nancy Grygiel?

The 2,010 Amgen shares reported are a grant classified as a “grant, award, or other acquisition,” not an open-market purchase. They were issued at a stated price of $0.00 per share as part of her compensation, according to the Form 4 transaction details.

How do dividend equivalents (DEs) affect Nancy Grygiel’s Amgen (AMGN) share count?

The filing notes 110 dividend equivalents credited under Amgen’s equity incentive plan, attached to Nancy Grygiel’s unvested RSUs. These DEs convert into Amgen common shares on a one-to-one basis as the underlying RSUs vest, with cash paid for any fractional remainder.

What Amgen (AMGN) shares are reported under Nancy Grygiel’s 401(k) plan?

Nancy Grygiel’s Form 4 shows 105.465 Amgen shares held indirectly through the company’s 401(k) plan. These represent her interests in Amgen’s stock fund within the plan as of the filing date, separate from her directly held common stock positions reported on the form.

Does this Amgen (AMGN) Form 4 show any insider sales by Nancy Grygiel?

The Form 4 does not report any insider sales by Nancy Grygiel. It records an acquisition of 2,010 Amgen shares via equity grant and lists updated direct and indirect holdings, including plan-related interests, without noting any disposition transactions in this filing.